Rumour Post On Halaal Street

SIMPLEX INFRA...

street walkers have it that this co may soon announce plans 2 diversify into THERMAL POWER.......

on 15th jan...the alert was flashed when mkts were off & power was on...
now , both r off.....!!!!!!

well said. Let us switch off everything and watch this blood bath

whts the rumour on ranbaxy ? any one knows here ?

STREET talks that BIYANI PROMOTED future group is likely 2 diversify into retailing of appartments (infra itch....????) though its formats in BIG BAZAAR...
.................................................. .................................................. ..
STATE BANK OF MYSORE....
back door whispers out that the proposed stock split is likely 2 b put on shelf........

on 12th nov....v had the inside story , now its OUT officially.....

one of the business daily has this story 2day.........pasted below.
.................................................. .................................................. ..


Biocon to list Syngene ..

Invests in US start-up IATRICa for new cancer drugs

Our Bureau

Bangalore, Jan. 17

Biocon on Thursday said it would list its subsidiary Syngene International Ltd, during the 2008-09 fiscal.

The board has approved the plan to list Syngene, ranked among Asia’s top contract research organisations (CROs), while a committee will suggest the modalities of the listing.

The company said it has picked up 30 per cent equity in a US research start-up by two Indians - IATRICa, Inc. – to develop new molecules against cancer and infectious diseases based on a proprietary immuno-conjugation technology. Biocon has initially invested under $10 million in the young company and the joint programme is to begin in April.

“Syngene has attained critical mass that can be leveraged to deliver a strong growth trajectory. As one of Asia’s largest and most profitable contract research companies, Syngene’s IPO can deliver superior shareholder value,” said Ms Kiran Mazumdar-Shaw, Biocon’s CMD.

Syngene during the year has already fetched revenue of Rs 150 crore and the listing would ensure that its potential will not get “masked by the overall consolidated business,” Ms Mazumdar Shaw told Business Line.

With global pharma companies finding it difficult to sustain research on their own, “The outsourcing opportunity is going to increase and the listing should fetch a much higher valuation for Syngene than for a discovery or biopharmaceutical company because the market understands outsourcing (better than it does) research,” she reckoned.

NOVEL CANCER DRUGS


Even as it pursues overseas acquisitions funded by the proceeds of selling its enzymes business,

Biocon has added new research partner: IATRICa was formed in 2007 with technology developed at the Johns Hopkins University, Maryland, and has exclusive licences to the immuno-conjugate technology invented by Johns Hopkins scientists and the company’s founders, Dr Atul Bedi and Dr Rajani Ravi.

Biocon’s co-developed anti-cancer drug BioMAB EGFR is already in the market. Ms Mazumdar-Shaw said any future products coming out of the IATRICa alliance would complement its range, in particular for solid tumours. They could be more potent and hopefully drive down the cost of cancer treatment, she said.

The company has begun label expansion trials of BIOMAb for Glioma, while it will begin trials for non-small cell lung cancer shortly

ORAL INSULIN


The company expects to begin phase II trials in India of its novel oral insulin, IN-105, in March. The drug is nearing completion of phase I clamp studies in Sweden.

The Biocon scrip closed marginally lower at Rs 540.60 on Thursday......

SKM should actually benefit from the bird-flu scare.

Regards,
Kalyan.

the insiders reveal that there may b a FIRM ALLOTMENT for REL POWER ipo to the retail guys............!

it will b chdambarams last budget......for this govt.
.................................................. ...............................................
WOCKHARDT HOSP.....
insiders reveal that CITI is likely 2 pick up stake pre IPO.....

No need for rumours The mgmt themselves have announced 15% pre-IPO placement to Citigroup.